Relevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B-cell lymphoma (SRPL)

L Baseggio; A Traverse-Glehen; E Callet-Bauchu; D Morel; J P Magaud; F Berger; G Salles; P Felman

doi:10.1002/hon.957

Relevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B-cell lymphoma (SRPL)

Hematol Oncol. 2011 Mar;29(1):47-51. doi: 10.1002/hon.957.

Authors

L Baseggio¹, A Traverse-Glehen, E Callet-Bauchu, D Morel, J P Magaud, F Berger, G Salles, P Felman

Affiliation

¹ Laboratoire d'Hématologie cellulaire, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France.

PMID: 20677173
DOI: 10.1002/hon.957

Abstract

'Splenic red pulp lymphoma with numerous basophilic villous lymphocytes' (SRPL), recently described, is characterized by clinical, morphologic, immunologic, cytogenetic and molecular features distinct from SMZL/SLVL and HCL. In particular, the intensity of CD11c staining (expressed as fluorescence intensity -RFI-) in SRPL is significantly different from the RFI in SMZL/SLVL and HCL. Moreover the use of a scoring system based on the expression of CD11c, CD22, CD76, CD38 and CD27 appears to improve the differential diagnosis between SRPL and SMZL/SLVL and emphasizes that SRPL is an entity closed to but distinct from SMZL/SLVL.

MeSH terms

Biomarkers, Tumor / analysis*
CD11c Antigen / analysis*
Diagnosis, Differential
Humans
Lymphoma, B-Cell / chemistry
Lymphoma, B-Cell / diagnosis*
Lymphoma, B-Cell / pathology
Lymphoma, Non-Hodgkin / diagnosis
Splenic Neoplasms / chemistry
Splenic Neoplasms / diagnosis*
Splenic Neoplasms / pathology

Substances

Biomarkers, Tumor
CD11c Antigen